Literature DB >> 11353800

An alpha4beta4 nicotinic receptor subtype is present in chick retina: identification, characterization and pharmacological comparison with the transfected alpha4beta4 and alpha6beta4 subtypes.

B Barabino1, S Vailati, M Moretti, J M McIntosh, R Longhi, F Clementi, C Gotti.   

Abstract

Retina from 1-day-old chicks is a valuable tissue model for studying neuronal nicotinic receptors because it expresses a large number of the developmentally regulated high affinity [(3)H]epibatidine labeled nicotinic receptors. Most of these receptors contain the beta4 subunit associated with different alpha subunits. Using a sequential immunodepletion procedure with anti-alpha6, anti-beta3, anti-beta2, and anti-beta4 antibodies, we purified an alpha4beta4 nicotinic receptor subtype that accounts for approximately 20 to 25% of the high affinity [(3)H]epibatidine labeled receptors present in retina at that developmental time. Immunoprecipitation and Western blotting experiments confirmed that the purified subtype contains only the alpha4 and beta4 subunits. This receptor binds a number of agonists and the antagonist dihydro-beta-erythroidine with nanomolar affinity, whereas it has micromolar affinity for the alpha-conotoxin MII and methyllycaconitine toxins and other nicotinic antagonists. Comparison of the pharmacological profile of this purified native subtype with that of the same subtype transiently expressed in human BOSC23 cells showed that they have very similar rank orders and absolute Ki values for several nicotinic drugs. Finally, because chick retina expresses an alpha6beta4-containing subtype with a high affinity for the alpha-conotoxin MII, we used native and transfected alpha4beta4 and alpha6beta4 subtypes to investigate the relative contributions of the alpha and beta subunits to this binding, and found that the alpha6 subunit determines the high affinity for this toxin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353800     DOI: 10.1124/mol.59.6.1410

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

1.  Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

Authors:  Michele Zoli; Milena Moretti; Alessio Zanardi; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.

Authors:  Kia J Jackson; Sarah S Sanjakdar; Pretal P Muldoon; J Michael McIntosh; M Imad Damaj
Journal:  Neuropharmacology       Date:  2013-02-13       Impact factor: 5.250

3.  Effects of benzothiazepines on human neuronal nicotinic receptors expressed in Xenopus oocytes.

Authors:  Francisco Sala; José Mulet; Luis Miguel Valor; Manuel Criado; Salvador Sala
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 4.  Naturally-expressed nicotinic acetylcholine receptor subtypes.

Authors:  Jie Wu; Ronald J Lukas
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

Review 5.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.